Brisbane, Australia, 11 March 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today provided an update on its direct-to-consumer product being developed under the Startup Creasphere program. In the program, ResApp collaborated with the consumer healthcare business unit of Sanofi on building a consumer health-focused product using ResApp’s novel respiratory disease diagnostic algorithms. As of the 8th of March, Sanofi has not exercised the option to enter into exclusive negotiations for a pilot phase under the scope of the Startup Creasphere program.
Tony Keating, CEO and Managing Director of ResApp commented, “We are excited about the possibilities of bringing our clinical-grade algorithms to a smartphone application for at-home consumer use, and we continue to advance the product with a number of interested parties.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional hardware. Clinical studies have demonstrated accurate diagnosis of lower respiratory tract disease, upper respiratory tract infection, pneumonia, bronchiolitis, croup, asthma exacerbation/reactive airway disease, chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation and obstructive sleep apnoea. ResApp’s smartphone-based acute respiratory disease diagnostic test, ResAppDx-EU, is CE Marked in the European Union and TGA approved in Australia. Potential customers of ResApp’s products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as humanitarian organisations in the developing world. For more information, visit www.resapphealth.com.au